STACY GILKEY: Open Payments
NPI 1740701978 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$371 in 15 payments from 8 companies in 2025. Trend: 2023 $786 · 2024 $113 · 2025 $371
Food & beverage: $371
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $119 |
| Alkermes, Inc. | 2 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Janssen Pharmaceuticals, Inc | 1 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| ABBVIE INC. | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
Products named: COBENFY, HETLIOZ, INVEGA SUSTENNA, VIVITROL, CAPLYTA, ARISTADA, REXULTI, VRAYLAR.
Industry payments across KY — which companies pay providers there.
